FDA authorizes first wearable device that monitors ketone and blood sugar levels (fda.gov)

Article summary

The FDA has authorized the first wearable device that continuously monitors both ketone and blood sugar levels, which can help people with diabetes detect warning signs of a dangerous complication. The device, called the Libre Duo 10 Day, can send automatic alerts if ketone levels reach a concerning threshold. This authorization is a breakthrough for the safety of children and adults living with diabetes. The device can help patients and caregivers recognize rising ketones before diabetic ketoacidosis becomes a medical emergency.

Main themes

• diabetes management
• wearable devices
• glucose monitoring
• ketone tracking
• athletic performance
• metabolic health
• hospital care
• non-invasive sensing technology

What commenters say

• Some commenters believe that the device could be used by athletes to improve performance by monitoring glucose and ketone levels.
• Others argue that the device would not provide actionable information for non-diabetic athletes.
• There is a discussion about the potential use of continuous glucose monitoring in hospital settings, but it is hindered by technical challenges.
• Some commenters think that the device could be useful for people trying to enter a fasted state or track their metabolic flexibility.
• The use of continuous glucose monitoring by non-diabetic individuals is seen as potentially beneficial for recovery and metabolic health, but also raises concerns about doping in competitive sports.
• The development of non-invasive glucose sensing technology is considered a challenging but important goal.
• The device's potential applications extend beyond diabetes management to areas such as cardiac surgery, burn units, and ICU care.